Abstract: An impact attenuation system comprises an aluminum honeycomb sheet having a top surface and a bottom surface. The aluminum honeycomb sheet defines a plurality of approximately hexagonally shaped cells. The bottom surface defines a single sheet of contiguous cells and the top surface defines two or more islands of contiguous cells separated by one or more slits. At least a portion of one or both of the top surface and bottom surface may be covered by a polymer skin. The polymer skin may comprise carbon fibers and/or fiberglass.

Abstract: An impact attenuation system comprises an aluminum honeycomb sheet having a top surface and a bottom surface. The aluminum honeycomb sheet defines a plurality of approximately hexagonally shaped cells. The bottom surface defines a single sheet of contiguous cells and the top surface defines two or more islands of contiguous cells separated by one or more slits. At least a portion of one or both of the top surface and bottom surface may be covered by a polymer skin. The polymer skin may comprise carbon fibers and/or fiberglass.

Abstract: An impact-attenuating liner for a helmet includes a liner body made from an impact-absorbing material and a plurality of pads removably attached to an interior surface of the liner body, each of the pads being repositionable at different locations on the interior surface of the liner body. A retention system may be attached to the liner body and configured to secure the liner to the wearer's head during use. The liner may be configured to provide substantially uniform impact protection throughout the interior region of the helmet.

Abstract: An impact attenuation system comprises an aluminum honeycomb sheet having a top surface and a bottom surface. The aluminum honeycomb sheet defines a plurality of approximately hexagonally shaped cells. The bottom surface defines a single sheet of contiguous cells and the top surface defines two or more islands of contiguous cells separated by one or more slits. At least a portion of one or both of the top surface and bottom surface may be covered by a polymer skin. The polymer skin may comprise carbon fibers and/or fiberglass.

Abstract: An impact-attenuating liner for a helmet includes a liner body made from an impact-absorbing material and a plurality of pads removably attached to an interior surface of the liner body, each of the pads being repositionable at different locations on the interior surface of the liner body. A retention system may be attached to the liner body and configured to secure the liner to the wearer's head during use. The liner may be configured to provide substantially uniform impact protection throughout the interior region of the helmet.

Abstract: A helmet cover assembly including a cover configured to extend over a helmet, at least one mounting device coupled to the cover; and one or more straps coupled to the at least one mounting device and configured to tighten the cover to the helmet. A helmet cover assembly including a cover configured to extend over a helmet, a first mounting device coupled to a first lateral side of the cover, a second mounting device coupled to a second lateral side of the cover, and an adjustable length strap coupled to the first mounting device and the second mounting device and configured to adjust the distance between the first mounting device and the second mounting device.

Abstract: A mount arm has a first end and a second end where the first end is configured to be mounted to a helmet. The mount arm has a first adjustment mechanism proximate the first end and is configured to position the second end of the mount arm relative to a user's eye when the mount arm is mounted to the helmet. A second adjustment mechanism is proximate the second end of the mount arm and is configured to position an optical member relative to the user's eye when the mount arm is mounted to the helmet. When the mount arm is mounted to the helmet, the mount arm is configured to pivot from an in-use position where the optical member is positioned in front of the user's eye to a stowage position where the optical member is moved out of the user's field of vision.

Abstract: The present invention is a PVC or rubber illuminating safety glove utilized without a power source that includes a plurality of finger and thumb sections that accommodate a user's fingers and thumb and include a plurality of distal ends and a plurality of fingertips that are located on the distal ends of the finger and thumb sections and include a chemical compound that is safely embedded into the distal ends that become illuminated when exposed to an electromagnetic field. The embedded chemical compound is a plurality of microscopic polymer beads or a plurality of supermagnetic iron oxide nanoparticles that illuminate color instantly and reversibly when exposed to the electromagnetic field.

Abstract: Pharmaceutical and/or veterinary formulation containing about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-forming agent comprising lecithin and an organic salt, and the balance stearin.

Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.

Abstract: A display device assembly for personal care items to be sampled includes a housing having an upper surface, a seat extending vertically down from the upper surface and a wall extending vertically up from the upper surface. The seat defines an interior cavity. A godet is disposed in the seat. The godet defines an interior cavity for storing the personal care item. The assembly includes a godet cover plate having an opening corresponding to the seat and a hook protruding from a perimeter of the godet cover plate. When assembled the godet cover plate rest on the upper surface of the housing and is held by frictional force of the hook and the wall such that the godet is secured within the seat. A cover is rotatably mounted to the housing and, when assembled, the cover encloses the upper surface to protect the personal care item stored in the godet.

Abstract: A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-foaming agent and the balance stearin. Such formulations provided release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.

Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.

Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.

Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15 % (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5 % (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.

Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.